Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ:BCLI opened at $0.34 on Thursday. The company has a market capitalization of $23.72 million, a P/E ratio of -1.06 and a beta of 0.43. Brainstorm Cell Therapeutics has a 1 year low of $0.13 and a 1 year high of $2.18. The business’s 50 day simple moving average is $0.46 and its 200 day simple moving average is $0.41.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. On average, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.